Peter Crane is the co-founder and CEO of Entelo Bio, a gene sequencing company combining cutting edge chemistry with machine learning to unlock transformative therapies for patients with chronic diseases.
With a career spanning lab automation, biomanufacturing and cancer proteomics (and as an investor in hard science Start-ups), it was his frustration with existing genomic methods that drove Peter and his 3 academic co-founders to spin Entelo Bio out of Oxford University in 2023.
Hungry to look at biology in a new way, their isoform sequencing platform aims to reduce the error rate and cost of long read single cell sequencing.
Listen here